Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Dupilumab helps severe asthma patients cut glucocorticoid use

Research has shown dupilumab reduces glucocorticoid use by more than 70% and the number of severe asthma exacerbations by almost 60%.

The atopic dermatitis treatment dupilumab may allow patients with severe asthma to reduce their oral glucocorticoid use while improving asthma control, according to the results of a study published in the New England Journal of Medicine (online, 21 May 2018)[1].

The trial involved 210 patients with glucocorticoid-dependent asthma who were randomly assigned to dupilumab 300mg or placebo injection every 2 weeks for 24 weeks.

By the last week of the intervention, those in the dupilumab group had a 70.1% decline in glucocorticoid use from baseline, compared with a 41.9% reduction in the placebo group. The dupilumab group also had 59% fewer severe exacerbations than the placebo group and significantly improved lung function.

Dupilumab is a monoclonal antibody that targets a key component in an allergic inflammatory signalling pathway. It was granted marketing authorisation for atopic dermatitis in the EU in September 2017.

The researchers noted that the results indicated a significant placebo effect. However, they concluded that “even with this level of placebo effect, patients in the dupilumab group had a significant additional benefit regarding multiple measures of asthma control”.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205133

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Asthma inhaler

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.